Effect of Reslizumab in Chronic Rhinosinusitis

Status unconfirmed · Phase 3 · Has a placebo group

Conditions studied: Sinusitis

In brief

The purpose of this study is to determine whether Reslizumab is effective for the treatment of chronic sinusitis.

Key facts

Study ID

NCT02799446

Run by

Joshua S. Jacobs

People needed

30

Starts

2016-06-01

Expected to finish

2019-07-01

Last updated by the study team

2018-02-01

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent
• Willingness and ability to comply with the requirements of the study
• Female or male patients ages 18-75 at the time of screening
• A diagnosis of chronic rhinosinusitis according to the clinical practice guideline (update) of the American academy of otolaryngology - head and neck surgery
• Elevated blood eosinophils
• Significant findings on computed tomography (CT) scan

You may not qualify if…

• Unable to sign informed consent form
• A woman that is pregnant or nursing a child
• Known hypersensitivity to Reslizumab
• Active cigarette smoking in the year prior to screening
• Known underlying immunodeficiency
• History of alcohol or drug abuse in the year prior to screening
• Other criteria may apply. Please contact the investigator for more information

Where it is running

• Allergy and Asthma Clinical Research — Walnut Creek, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.